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ABSTRACT
Objective To determine whether offering self sampling of
cervicovaginal material for high risk human
papillomavirus (HPV) testing is an effective screening
method for women who do not attend regular cervical
screening programmes.
Design Cohort study (the PROHTECT trial).
Settings Noord-Holland and Flevoland regions of the
Netherlands, December 2006 to December 2007,
including 13 laboratories, gynaecologists, and more than
800 general practitioners.
Participants 28073 women who had not responded to
two invitations to the regular cervical screening
programme: 27792 women were assigned to the self
sampling group and invited to submit a self collected
cervicovaginalsampleforHPVtesting;281wereassigned
to the recall control group and received a second re-
invitation for conventional cytology.
InterventionWomenwithapositiveresultonthehighrisk
HPV test on their self sample material were referred to
their general practitioner. Women with abnormal results
on cytology were referred for colposcopy. Women with
normal results on cytology were re-evaluated after one
yearbycytologyandhighriskHPVtestingandreferredfor
colposcopy if either result was positive.
Main outcome measures Attendance rate in both groups
and yield of cervical intraepithelial neoplasia grade II/III
or worse (≥CIN II/≥CIN III) in self sampling responders.
Results The compliance rate in the self sampling group
was significantly higher than in the control group (crude
26.6% v 16.4%, P<0.001; adjusted 27.5% v 16.6%,
P<0.001). The number of detected ≥CIN II and ≥CIN III
lesionsinselfsamplingresponderswas99(1.3%)and76
(1.0%), respectively. Self sampling responders who had
not participated in the previousround of screening(43%)
had increased relative risks of ≥CIN II (2.04, 95%
confidence interval 1.27 to 3.28) and ≥CIN III (2.28, 1.31
to 3.96) compared with self sampling women who had
been screened in the previous round (57%).
Conclusions Offering self sampling by sending a device
for collecting cervicovaginal specimens for high risk HPV
testingtowomenwhodidnotattendregularscreeningisa
feasible and effective method of increasing coverage in a
screening programme. The response rate and the yield of
high grade lesions support implementation of this
method for such women.
Trial registration ISRCTN45527158.
INTRODUCTION
The introduction of organised cervical cancer screen-
ing programmes in Western countries has contributed
to a decrease in incidence of and mortality from cervi-
cal cancer. Nevertheless, one major problem concern-
ing the effectiveness of current cervical screening
programmes remains non-attendance.
1-4
Non-participating women (that is, non-attendees)
are at increased risk of cervical cancer.
56 Therefore,
targeting non-attendees is important in achieving opti-
mal protection from screening programmes. Offering
self sampling of cervicovaginal material for screening
has been suggested as a way of increasing screening
compliance.
178
Cytomorphologicalevaluationofselfsampledcervi-
covaginal specimens for detection of high grade cervi-
cal lesions has been shown to be inferior compared
withcervicalsamplesobtainedbyaphysician.Conver-
sely, high risk HPV testing on self collected cervicova-
ginalsampleshadatleastsimilarsensitivityforcervical
intraepithelial neoplasia grades II/III or worse (≥CIN
II/≥CIN III) compared with cytological reading of a
corresponding cervical sample collected by a
physician.
9-12
METHODS
Patients and procedures
PROHTECT (protection by offering HPV testing on
cervicovaginalspecimenstrial)isacohortstudywithin
the setting of the Dutch population based cervical
screening programme to assess the feasibility and
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for high risk HPV testing to women who do not attend
theregularscreeningprogramme.IntheDutchscreen-
ing programme, women aged 30-60 are invited once
every five years. Non-attendees living in the counties
of Noord-Holland or Flevoland (n=28073) who had
received their screening invitation in 2005 were
selected from the regional health council registry. In
the screening programme women are asked to make
an appointmentto have a smear takenby their general
practitioner or assistant. Opportunistic smears are dis-
regarded but results are registered in the nationwide
pathology database (PALGA). There is no charge for
womenparticipatinginprimarycervicalscreening,but
the costs for the necessary follow-up in cases of abnor-
mal cytology can be recovered from health insurance
companies. A “non-attendee” was defined as a woman
who neither responded to the regular invitation nor to
a standard reminder after six months. Women with
previous hysterectomy were excluded.
With a computerised random number generator
non-attendees were assigned in a 99:1 ratio to either
receive a kit (Delphi Screener (previous Pantarhei-
Screener/Mermaid))tocollectcervicovaginalmaterial
for subsequent testing for high risk HPV hybrid cap-
ture II (self sampling group, n=27792) or to receive a
second recall for conventional cytology (recall control
group,n=281).TheDelphiScreenerisalavagedevice,
designed to rinse the upper vagina and cervix and, in
combination with HPV testing, has been shown to
allow detection of similar high grade yields of CIN to
those achieved in cervical smears collected by
physicians.
9 The skewed ratio ensured adequate
powertodetectahigherattendancerateintheselfsam-
pling versus second recall arm, while at the same time
maximising the ≥CIN II/≥CIN III rate among self
sampling responders. The pre-randomised self sam-
plingandrecallcohortswererecruitedfromDecember
2006 to April 2007, and women were invited to
respond within six weeks after the mailing. Only
responses received up to December 2007 were scored
for analysis.
All invited women were written to at their home
address the week before to give notice of receipt of a
second recall letter (recall control group) or a self sam-
ple kit (self sampling group). Women in the recall con-
trol group received an official second reminder to visit
theirgeneralpractitionerforconventionalcytology,an
explanatory letter, and an informed consent form.
Womenintheself samplinggroupreceivedaself sam-
ple kit with an explanatory letter,
9 a collection tube,
instructions (written and drawn), an informed consent
form, and a return box with the address of the testing
laboratory. A telephone helpline and website provid-
ing information on the trial (www.hpvthuistest.nl) was
available throughout the study.
HPV testing and follow-up algorithm
Women in the self sampling group were asked to send
the collection tube containing their cervicovaginal
lavage specimen with the signed informed consent
form to the laboratory for high risk HPV testing.
Each specimen was tested with the hybrid capture II
high risk HPV DNA method at the laboratory. The
resultsoftheconfirmatoryHPVsamplestakenbygen-
eral practitioner (see below) were also based on the
hybrid capture II tests. On arrival in the laboratory,
lavage specimens were concentrated by spinning
down, removing all supernatant, and resuspending
the pellet in universal collection medium. If no clear
cellpelletswerevisible,sampleswereconsideredinva-
lid for testing.In such cases, the womanwas senta sec-
ond kit to repeat the self sampling at home. Valid
samples were subjected to the hybrid capture II high
risk HPV DNA test in an automated format on a rapid
capture system), according to the manufacturer’s
instructions (Qiagen, Gaithersburg, MD, USA). This
test is designed to detect high risk HPV types 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Results
were expressed as relative light units per cut-off value
(RLU/CO). Women with a positive result (RLU/CO
≥1)wereinstructedtovisittheirgeneralpractitionerfor
their doctor to take a cervical sample for cytology and
confirmatory HPV testing in the regional laboratory
serving the general practitioner. Women with abnor-
malcytologyresults(thresholdborderlineormilddys-
karyosis) were referred for colposcopy. Cytology of
cervical smears taken by the physician was carried
out in local laboratories, and results were reported
according to the CISOE-A classification, the standard
classification system for cytology in the Netherlands,
which can easily be translated into the Bethesda
classification.
10 In brief, on the basis of either squa-
mous or columnar abnormalities, cytology results are
categorised into three groups (normal, borderline or
mild dyskaryosis, and moderate dyskaryosis or
worse). Borderline or mild dyskaryosis corresponds
in the Bethesda classification to ASCUS\LSIL. Endo-
metrial abnormalities were excluded.
Independent of the HPV test result on the specimen
taken by the physician, women with normal cytology
results received advice for repeat testing (cytologyand
HPV testing) after a year and were referred for colpo-
scopy in case of a positive HPV or cytology test result
(threshold ≥borderline or mild dyskaryosis). Women
withnegativeresultsonbothtestswerereferredbackto
the national screening programme as their risk of a
clinically relevant lesion was considered too low to
warrant referral for colposcopy.
11 Colposcopy direc-
ted biopsies were taken for histological examination
from suspected areas on the cervix according to stan-
dard procedures in the Netherlands.
1213 Histological
examination was done in local pathology laboratories
and specimens were classified as CIN 0 (that is, within
normal limits or including any non-neoplastic lesion
such as inflammation, cyst, etc), I, II, or III, or as inva-
sive cancer, according to international criteria.
1415 On
the basis of biopsy results, women were treated in
accordance with the guidelines of the national screen-
ing programme.
16 Based on the cytology results, parti-
cipating women in the recall control group were
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Statistical analysis
Power calculation
Forthepowercalculation,weestimatedthepopulation
of non-attendees in the study area to be 45000 in the
year 2005. We further assumed 10% of these women
would not be eligible and that the response rate in the
self sampling group would be 15% higher than in the
recall control group. The power calculation was based
onourpreviouspilot,
1whichshowedcompliancerates
of 17.6% and 31.5% in the recall control and self sam-
plinggroups,respectively(twosidedttest;α0.05;99:1
randomisation; power 0.99999). We chose a 99:1 ran-
domisationtoprovidesufficientpowertodetectdiffer-
ences in compliance and to maximise the yield of
≥CIN II/≥CIN III in the self sampling cohort.
Response rate
All trial data were managed within a customised data-
base. The self sampling response was counted on the
basis of receipt of informed consent forms plus self
samples, and the response of the recall control group
wascountedonthebasisofreceiptofinformedconsent
forms as well as through the nationwide network and
registry of histopathology and cytopathology in the
Netherlands (PALGA; Bunnik, Netherlands). For
computing the response rate we included all women
who responded actively within 12 months after their
invitation to participate in this trial and compared
response rates of the groups with χ
2 test. In addition
to the crude response rates, we also compared the
response rates adjusted for women who during the
study reported they were not eligible because of pre-
vious hysterectomy.
HPV prevalence and yield of high grade CIN and cervical
cancer
Only self sampling material sent in within a year after
the invitation was included in HPV prevalence analy-
sis. The 18 month cumulative yields of ≥CIN II and
≥CIN III in women in the self sampling group who
submitted a specimen were obtained through the
PALGA database. If necessary, physicians were con-
tacted directly for additional clinical data.
Assessment of screening history self sampling responders
Programmed screening in the Netherlands involves
seven cytology invitations during a lifetime to women
aged 30-60—that is, every five years. The PALGA
database provided the screening history of attendees
in the two groups.
18 In analysing the screening history
amongthewomenwhohadbeeninvitedforaprevious
round of screening (that is, those aged ≥34), women
wereconsideredtohavemissedthepreviousscreening
round if a smear sample had not been taken within the
past seven years.
Risks of ≥CIN II and ≥CIN III were calculated for
women aged ≥34 who did not participate in the pre-
vious round relative to those who were screened in
the previous round. The relative risks were adjusted
for age by the Mantel-Haenszel method, with age stra-
tified at 34-38, 39-43, 44-48, 49-53, 54-58, and ≥59.
Women aged ≤33 could not have a screening history
because of their age and were excluded. The associa-
tion between the relative risks and age, as well as
between the relative risks and screening history, were
tested by the Mantel-Haenszel test of homogeneity.
RESULTS
Characteristics of trial cohort
Figures 1 and 2 show the flow of women through the
study.Thepublichealthdatabaseindicatedthat28073
women in the 2005 cohort who received an invitation
to screening in the study area were registered as non-
attendees, instead of the expected 45000. Of these,
27792 were allocated to the self sampling arm and
281 to the recall control arm. During the study 906
women (3.3%) in the self sampling group and four
women(1.4%)intherecallcontrolgroupreportedhav-
inghadahysterectomy,leaving26886eligiblewomen
in the self samplinggroup and 277 in the recallcontrol
group. There were no significant differences between
the age distributions in both arms.
Participation rate
In the self sampling group, 7404 of 27792 (26.6%)
women sent a self sampled specimen for HPV testing
and51(0.2%)decidedtovisittheirgeneralpractitioner
for conventional cervical cytology. When we adjusted
for women whowere not eligible because of hysterect-
omy,thepercentageofwomenwhorespondedbysub-
mitting a self sample was 27.5%. The self sampling
response rate did not vary with age (Pearson χ
2=7.15,
df=6; P=0.307).
Intherecallcontrolgroup,46of281(16.4%)women
visited their general practitioner for cervical cytology.
After adjustment for non-eligibility, the response rate
was 16.6% (46/277). Taken together, the difference in
compliance rates between the groups was 10.2%
Women who did not attend regular
screening programme in 2005 (n=28 073)
Randomisation
Self sampling group
(n=27 792)
Participation (n=7404)
Valid HPV test result (n=7384)
Recall control group
(n=281)
Excluded because of
hysterectomy (n=906)
Invalid HPV test
result (n=20)
Participation (conventional
cytology at general
practitioners) (n=46)
Excluded because of
hysterectomy (n=4)
Fig 1 | Study design for comparison of compliance rates
between recall control group and self sampling group
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14.6%, P<0.001) or 10.9% (27.5% v 16.6%, 6.5% to
15.3%, P<0.001) after adjustment for those who were
not eligible.
To evaluate whether screening history had an effect
on participation in women allocated to self sampling,
we compared the screening history of women in the
recall control group (n=277) with women in the self
sampling group (n=26886). When we excluded
women aged <33 because they could not have a
screening history (49 in the recall control group and
3398 in the self sampling group), 228 eligible women
were left in the recall control group and 22988 in the
selfsamplinggroup.Therewere34and6227attendees
aged ≥34, respectively. Of the 228 womenin the recall
controlgroup,61(26.8%)hadhadasmeartakeninthe
past seven years, compared with 5967 (26.0%) of the
22988womenintheselfsamplinggroup,indicatingno
significant differences.
We examined the effect of having no smear in the
past seven years on attendance of women in the recall
control group compared with the effect on attendance
in the self sampling group. In the recall control group
9.0% (15/167) of the women responded to recall com-
pared with 15.8% (2694/17021) of the women in the
self sampling group. Thus, the relative risk for partici-
pation of women without a smear in the past seven
years in the self sampling group was 1.76 (1.09 to
2.86) compared with women who had no smear in
the past seven years in the recall control group
(P=0.016).
For the women who had had a smear in the past
seven years, these proportions were 19/61 (31.1%)
for the recall control group and 3533/5967 (59.2%)
for the self sampling group, resulting in a relative risk
ofparticipationintheselfsamplinggroupof1.90(1.31
to 2.76, P<0.001). As the relative risks of participation
of women who had or had not had a smear in the past
sevenyearsdidnotdiffer(1.90v1.76,P=0.80),itseems
unlikely that screening history introduced bias in the
participationofwomeninselfsamplinginbothgroups.
HPV detection rate self sampling attendees
Of the 7404 women who submitted a self collected
sample, 7384 (99.8%) had a valid hybrid capture II
test result (fig 1) and 757 (10.3%) were positive for
high risk HPV (fig 2). The percentage positive for
HPV decreased with age (t=−6.77; P<0.001) until age
39-43, when a plateau was reached (t=−0.30; P=0.77).
Women who had positive results for high risk HPV
were advisedtovisit theirgeneralpractitionerforboth
conventionalcytologyandasecondhighriskHPVtest
onacervicalsamplecollectedbythephysician.Avalid
HPV result was recorded for 491, and 288 (58.7%)
werepositiveforcervicalHPV.Ofthe203withanega-
tive result, 81 (39.9%) originally displayed hybrid cap-
ture II RLU/CO values <2 on the self collected
sample. Conversely, only 21 (7.3%) with a positive
result had a RLU/CO value <2 on the self sample.
Compliance with follow-up
Of the self sampling attendees with positive HPV
results, 90.4% (684/757) complied with follow-up
with their general practitioner. Of these 684, 437
(63.9%) followed the trial protocol and had both cytol-
ogy and HPV test results, whereas 61 (8.9%) had only
an HPV test and 186 (27.2%) had only a cytology test.
Thus 623/757 (82%) women had cytological follow-
up.Atotalof182(26.6%)womenhadabnormalresults
on cytology, of whom 150 (82.4%) adhered to the
direct referral advice for colposcopy. The 502 remain-
ing women (73.4%) were advised have a repeat testing
HPV positive (n=757, 10.3%)
Follow-up with general practitioner (n=684/757, 90.4%)
HPV negative (n=6627, 89.7%)
Invited for next round of cervical screening
Attendees in PROHTECT study with validated HPV test (n=7384)
CIN 0/I (n=50, 27.5%)
≥CIN II (n=94, 51.6%)
Follow-up (n=6, 3.3%)
No histology, but repeat cytology:
Normal cytology (n=18, 9.9%)
BMD (n=3, 1.6%)
>BMD (n=1, 0.5%)
No follow-up (n=10, 5.5%)
Direct referral advised (≥BMD)
(n=182/684, 26.6%)
HPV positive or ≥BMD
(n=65/502, 12.9%)
CIN 0/I (n=20, 30.8%)
≥CIN II (n=5, 7.7%)
No follow-up (n=40, 61.5%)
HPV negative and/or normal
cytology (n=223/502, 44.4%)
Advised for repeat testing after 1 year (normal cytology or no cytology) (n=502/757, 73.4%)
No follow-up
(n=214/502, 42.6%)
No response (n=73, 9.6%)
Fig 2 | Study design for evaluation of yield of ≥CIN II in women of self sampling group (BMD=borderline or mild dyskaryosis)
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titioner,and287(57.2%)complied.Basedonapositive
high risk HPV result or cytology result, or both, 65
(12.9%) women were advised to undergo colposcopy
and 25 (38.5%) of them did so.
Yield of high grade CIN and cervical cancer
Among the 150 women with ≥borderline or mild dys-
karyosis who visited a gynaecologist at baseline, 94
≥CIN II lesions were detected, including five invasive
carcinomas. Furthermore, five ≥CIN II lesions were
detected among the 25 women who complied with
the referral for colposcopy after repeat testing at one
year. The cumulative 18 month yields of ≥CIN II and
≥CIN III in women with a positive HPV self sampling
test were 1.3% (99/7384) and 1.0% (76/7384), respec-
tively (table 1).
Yield of high grade CIN and cervical cancer in relation to
screening history
Among women aged ≥34, those who did not have a
cervical smear taken at the previous round had more
≥CIN II (relative risk 2.04, 1.27 to 3.28, P=0.003;
table 2) and more ≥CIN III (2.28, 1.31 to 3.96,
P=0.003;table 3) thanwomenwhodidhaveacervical
smear at the previous round. This association between
screeninghistoryandcervicalintraepithelialneoplasia
wasnotrelatedtoage(PvaluesMantel-Haenszeltestof
homogeneity 0.639 for ≥CIN II and 0.515 for ≥CIN
III). All five carcinomas were detected in women
aged ≥34 who had not been screened at the previous
round.
DISCUSSION
In the Netherlands in 2005, 65% of women attended
thecervicalscreeningprogramme(annualreportofthe
regular screening programme, 2006, www.bevolking
sonderzoek.info/). By offering self sampling to non-
attendees, and taking into account the 18% loss of
cytology in the follow-up in this group, the real effect
on attendance in the screening programme would be
an extra 5.2% (6.3% (27.5% of 23%)*(100%−18%)).
The total attendance in the screening programme
would then increase to 70.2% (5.2%+65%). Moreover,
we showed that the cumulative incidence of ≥CIN II
yield in our study was 1.3% (99/7384), while the CIN
lesions found via regular screening programme in
2005 was 0.8% (data received from PALGA).
Screening history of non-attendees
The finding of a twofold and more than twofold rela-
tive risk of ≥CIN II and ≥CIN III, respectively, in self
samplingwomenaged≥34whodidnotattend thepre-
vious screening round is in line with the assumption
thatbackgroundriskfor≥CINII/≥CINIIIisincreased
afterwomenmissonescreeninground.Intheselfsam-
pling group, the association between screening history
andCINwasindependentofage(P=0.639for≥CINII
and 0.515 for ≥CIN III).
Strengths and limitations
We did not include a recall control group for compar-
ison of yield of ≥CIN II/≥CIN III with the self sam-
pling group because data from our previous work
indicated that non-attendees of the regular screening
programme respond poorly to any repeat invitation
letter.
1 Instead, we used a randomisation ratio of self
samplingversusrecallwomeninfavourofmaximising
detection of ≥CIN II/≥CIN III in the self sampling
group to allow an accurate assessment of the yield
achieved by self sampling combined with HPV testing
in non-attendees.
Table 1 |Yields of ≥CIN II/III in women who carried out
cervical self sampling (categorised by age)
Age (years) No of women
No (%) with
≥CIN II
No (%) with
≥CIN III
≤33 1157 29 (2.5) 23 (2.0)
34-38 1497 30* (2.0) 23* (1.5)
39-43 1266 10* (0.8) 6* (0.5)
44-48 1139 11* (1.0) 8* (0.7)
49-53 918 9* (1.0) 7* (0.8)
54-58 825 6 (0.7) 5 (0.6)
≥59 582 4* (0.7) 4* (0.7)
Total 7384 99† (1.3) 76† (1.0)
Total (excluding
age ≤33)
6227 70† (1.1) 53† (0.9)
*One carcinoma.
†Five carcinomas.
Table 2 |Yield and risk of ≥CIN II in women aged ≥34 in relation to participation in previous round of screening (categorised
by age)
Age (years)
Screened in previous round
Not screened in previous
round Rate of participation in
previous round (95% CI)
Relative risk (95% CI) of
≥CIN II No of women ≥CIN II No of women ≥CIN II
34-38 809 13 688 17* 54.0 (51.5 to 56.6) 1.54 (0.75 to 3.14)
39-43 721 4 545 6* 57.0 (54.2 to 59.7) 1.98 (0.56 to 7.00)
44-48 684 3 455 8* 60.1 (57.2 to 62.9) 4.01 (1.07 to 15.03)
49-53 531 5 387 4* 57.8 (54.7 to 61.0) 1.10 (0.30 to 4.06)
54-58 463 2 362 4 56.1 (52.7 to 59.5) 2.56 (0.47 to 13.89)
≥59 325 — 257 4* 55.8 (51.8 to 59.9) —
Total 3533 27 2694 43† 56.7 (55.5 to 58.0) 2.04 (1.26 to 3.28)
*Including one carcinoma.
†Including five carcinomas.
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unlike responders to a re-invitation for cytology, self
sampling responders might have been more likely to
respond for curiosity reasons, despite already being
opportunistically screened before the study invitation.
To address this we analysed the effect of screening his-
tory on participation via self sampling versus a second
recall. When we took into account the screening his-
toryofwomenrespondersaged≥34inbotharms,there
was no indication that previously screened women
would have a relatively higher preference for self sam-
pling than women who were not screened within the
past seven years.
Interestingly, self sampling responders showed high
adherence to direct follow-up regimens, both at the
general practitioner level (90.4%) and at the level of
direct referral for colposcopy (94.5%). In size the latter
is comparable with follow-up compliance of attendees
of the Dutch screening programme (91%).
16 Compli-
ance after repeat testing advice (59% of women
attended after one year), however, was markedly
lower than observed in regular screening attendees
with similar advice (86%).
19 This rather low return
rate might be influenced by the fact that most of these
women had previous normal cytology test results after
a smear taken by a physician.
In 41% of the women who had an HPV test on both
self and physician collected samples, a positive result
for high risk HPV in the self sample could not be con-
firmed in the sample taken by the physician. Most of
thesediscrepanttestresultswere foundinwomenwith
lowhybridcaptureIIRLU/COvalues.Inselfsampled
specimens more HPV infections of vaginal origin,
including those of low risk HPV types, might be
detected by hybrid capture II.
20-25 Even with a cut-off
level ofa positiveresultonhybrid captureIIincreased
to RLU/CO ≥2, there are still discrepancies between
positive results for HPV in the self sampled specimens
and smears taken by the general practitioner. In that
case the total number of HPV positive cases would
decrease from 757 to 627, but we would miss six
≥CIN II lesions (two CIN II, and four ≥CIN III).
Interestingly, the yields of ≥CIN II and ≥CIN III in
self sampling responders who attended the previous
round and the yields in regular screening responders
of the same age tested for high risk HPV by general
primer 5+/6+ polymerase chain reaction (GP5+/6+
PCR) were identical (0.8% and 0.5%,
respectively).
2627 This strongly suggests that the ≥CIN
II/≥CIN III sensitivity of HPV testing in self sampled
cervicovaginal material is not inferior to that of HPV
testingonsmearstakenbyaphysician.Thisisinagree-
mentwitharecentmeta-analysisthatindicatedthatself
samplingisassensitiveasphysicianobtainedsampling
to detect high risk HPV.
25 Collectively, our data show
thattargetedeffortsshouldbemadetoscreenself sam-
pling non-attendees who missed a previous screening
round, given their increased risk of clinically relevant
cervical disease.
Wehavealsoshownthatthechosentriagealgorithm
of a cytology test on a conventional smear after an
HPV positive self sample is successful. A substantial
subsetofthe10%selfsamplingwomenwhowereposi-
tiveforhighriskHPV,however,seemedtohavenega-
tivecytologyresultsandbenegativeforhighriskHPV
at follow-up, which in practice resulted in a marked
number of unnecessary visits to the general practi-
tioner for these women. Therefore, alternative triage
toolsapplicabletoselfsampledmaterialshouldbecon-
sidered to prevent redundant sampling by general
practitioners. In this context, molecular methylation
markers,
28 which are currently being investigated, are
highly promising when applied to self sampled speci-
mens. Furthermore, efforts are ongoing to improve
liquidbasedcytologicalpreparationsofcervicovaginal
lavage fluids for detecting abnormal cells.
Conclusions
It is feasible and effective to offer women who do not
attend regular cervical screening programmes the
choice of self sampling by sending a device for collect-
ing cervicovaginal specimens for high risk HPV test-
ing. This should lead to increased coverage and
marked detection of ≥CIN II/≥CIN III lesions, parti-
cularly in women who have not attended the previous
roundofscreening.Implementation islikelyto payoff
immediately in terms of protecting a subset of non-
attendeesknowntobeatincreasedriskofcervicalcan-
cer.
Table 3 |Yield and risk of ≥CIN III in women aged ≥34 in relation to participation in previous round of screening (categorised
by age)
Age (years)
Screened in previous round
Not screened in previous
round Rate of participation in
previous round (95% CI)
Relative risk (95% CI) of
≥CIN III No of women ≥CIN III No of women ≥CIN III
34-38 809 11 688 12* 54.0 (51.5 to 56.6) 1.28 (0.57 to 2.89)
39-43 721 2 545 4* 57.0 (54.2 to 59.7) 2.65 (0.49 to 14.39)
44-48 684 2 455 6* 60.1 (57.2 to 62.9) 4.51 (0.91 to 22.25)
49-53 531 3 387 4* 57.8 (54.7 to 61.0) 1.83 (0.41 to 8.13)
54-58 463 1 362 4 56.1 (52.7 to 59.5) 5.12 (0.57 to 45.57)
≥59 325 — 257 4* 55.8 (51.8 to 59.9) —
Total 3533 19 2694 34† 56.7 (55.5 to 58.0) 2.28 (1.31 to 3.96)
*Including one carcinoma.
†Including five carcinomas.
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